Santen Pharmaceutical Co., Ltd. held its 114th Annual General Meeting of Shareholders.
The Meeting started at 10:00 a.m. and ended at 11:00 a.m., and the number of shareholders attended was 48.
| Matters reported: | - Business Report, Consolidated Financial Statements and Non-consolidated Financial Statements for the 114th Business Term (April 1, 2025 to March 31, 2026)
- The Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the consolidated Financial Statements for the 114th Business Term (April 1, 2025 to March 31, 2026)
|
|---|
| Questions: | We received questions regarding the following subjects from shareholders in advance and answered each question on the Meeting.
- How does the Company plan to incorporate AI into its future growth strategy?
- What governance framework has the Company established to address risks associated with the use of AI?
- What factors were considered in maintaining the year-end dividend for fiscal 2025 at the previous level?
- What initiatives is the Company pursuing to enhance its share price going forward?
We received questions regarding the following subjects from 3 shareholders attended and responded in kind.
- Is there a possibility of treating cataracts with eye drops instead of surgery?
- What is the Company's current status regarding expansion into North and South America?
- What are the effects of the treatment for acquired blepharoptosis?
- Regarding distribution channel of the blepharoptosis treatment. (over-the-counter or prescription drug).
- The Company's medium- to long-term global growth strategy for ophthalmic solutions designed to slow myopia progression
|
|---|
| Matters resolved: | Two proposals were all resolved.
Please refer to the Resolution Notice (PDF: 106KB)PDF file.Page will open in a new window. for detailed resolutions. |
|---|
